A2 Biotherapeutics is designing novel cell therapies to treat serious illnesses. Therapeutics to treat cancers depend on methods to distinguish tumors from normal cells. A2 Bio is using their proprietary Tmod platform to innovate new treatments for solid tumors involving the immune system. The platform integrates multiple signals, overcoming conventional single-target therapies, and exploits tumor-specific vulnerabilities. The Tmod platform is robustly different from other cell therapy systems due to its tumor precision and efficacy by incorporating two receptors, an activator and a blocker, to modulate the immune system. As their platform is modular, A2 Bio is building a broad pipeline of both autologous and allogeneic cell therapies for many unexploited tumor targets.
Claim company profile to post jobs directly on this page and this website.